In breast cancer, trastuzumab deruxtecan has been shown to exhibit a durable therapeutic activity in a population of heavily pretreated patients (≥2 prior anti–HER2-based regimens) with advanced HER2-positive breast cancer [31]. The gene discussed is ERBB2; the disease is breast cancer.